Baird Financial Group Inc. acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) in the second quarter, Holdings Channel reports. The institutional investor acquired 3,895 shares of the company’s stock, valued at approximately $236,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. grew its stake in shares of CRISPR Therapeutics by 1,128.0% in the 1st quarter. CarsonAllaria Wealth Management Ltd. now owns 614 shares of the company’s stock worth $39,000 after buying an additional 564 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of CRISPR Therapeutics by 159.2% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 635 shares of the company’s stock worth $39,000 after acquiring an additional 390 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of CRISPR Therapeutics by 21.0% in the 2nd quarter. Allworth Financial LP now owns 737 shares of the company’s stock worth $45,000 after acquiring an additional 128 shares during the last quarter. Pinnacle Holdings LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $48,000. Finally, Twin Lakes Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 80.4% in the 1st quarter. Twin Lakes Capital Management LLC now owns 772 shares of the company’s stock worth $48,000 after acquiring an additional 344 shares during the last quarter. 70.56% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on CRSP shares. TheStreet lowered shares of CRISPR Therapeutics from a “c” rating to a “d” rating in a report on Thursday, August 18th. Credit Suisse Group lowered their target price on shares of CRISPR Therapeutics from $90.00 to $78.00 in a report on Wednesday, November 2nd. SVB Leerink lifted their price objective on shares of CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a report on Monday, November 7th. Morgan Stanley initiated coverage on shares of CRISPR Therapeutics in a report on Tuesday, October 11th. They set an “underweight” rating and a $37.00 price objective for the company. Finally, Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $164.00 to $154.00 and set a “buy” rating for the company in a report on Tuesday, August 9th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $101.44.
Insider Transactions at CRISPR Therapeutics
CRISPR Therapeutics Stock Down 0.8 %
Shares of CRISPR Therapeutics stock opened at $55.03 on Thursday. The firm’s 50 day moving average price is $58.68 and its 200-day moving average price is $64.43. CRISPR Therapeutics AG has a 52-week low of $42.51 and a 52-week high of $86.95. The company has a market cap of $4.31 billion, a P/E ratio of -6.25 and a beta of 1.71.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its quarterly earnings data on Tuesday, November 1st. The company reported ($2.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.30) by $0.06. CRISPR Therapeutics had a negative net margin of 4,831.79% and a negative return on equity of 31.34%. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $3.53 million. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -9.23 EPS for the current fiscal year.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.